NCT05003453

The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema

The Effectiveness of a Topical Palmitoylethanolamide Formulation (Levagen+) for Reducing the Symptoms of Eczema Versus a Comparator

• Status: Completed
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: RDC Clinical Pty Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a double blind, randomised, non-clinical study with 2 groups (1 investigational group and 1 comparator group) aiming to assess the effectiveness of PEA for reducing eczema severity compared to a base comparator moisturiser in healthy adults aged over 18 years.

Conditions

• Eczema, Atopic

Interventions

Type	Name	Description
DRUG	1.5% Palmitoylethanolamide (PEA) sold as Levagen+	A topical cream containing 1.5% PEA applied to the affected site 2-times daily, liberally to coat and cover affected area.
DRUG	Placebo Comparator	A comparator placebo topical moisturiser cream (an unscented moisturising base cream) applied to the affected site 2 times daily, liberally to coat and cover affected area.

Timeline

• Start date: 2021-11-29
• Primary completion: 2022-06-03
• Completion: 2022-06-30
• First posted: 2021-08-12
• Last updated: 2023-11-18

Locations

1 site across 1 country: Australia